1. Market Research
  2. > Pharmaceutical Market Trends
  3. > India Pharmaceutical & Healthcare Industry 2H12

India Pharmaceutical & Healthcare Industry 2H12

  • March 2013
  • -
  • Emerging Markets Direct Media Holdings
  • -
  • 29 pages

India Pharmaceutical & Healthcare provides an overview of the industry in Asia Pacific and India. India’s pharmaceutical industry grew by 9.7% year-on-year in 2009-10, largely due to robust growth in the domestic market. India’s healthcare industry is expected to grow 14% per year to reach USD 280 billion by 2020. Exports of drugs, pharmaceuticals and fine chemicals accounted for approximately 4.20% of the total national exports in 2010-11.

The report includes the market trends and outlook for the pharmaceutical and healthcare industries in India. We examine the country’s generic production, healthcare equipments, government schemes, TRIPS Compatibility, R&D initiatives, Pharmaceutical Export Promotion Council and India’s Vision 2015.

Also, the report encompasses the profile of leading players in the industry as well as their financial highlights and SWOT analysis. Among the leading players are Ranbaxy, Dr Reddy’s, Cipla and Lupin. Ranbaxy is India’s largest pharmaceutical company with operations in 23 of the top 25 pharmaceutical markets of the world.


Table Of Contents

India Pharmaceutical and Healthcare Industry 2H12
1 Industry Profile
1.1 Asia-Pacific Overview
1.2 General Overview of India
1.3 India Pharmaceutical Industry
1.3.1 Domestic Pharmaceutical Industry
1.3.2 Pharmaceutical Exports and Imports
1.3.3 Central Pharma Public Sector Undertakings (CPSUs)
2 Market Trends and Outlook
2.1 Indian Generics Production
2.2 Healthcare Equipment
2.3 Government Schemes
2.4 TRIPS Compatibility and India
2.5 Research and Development (RandD) Initiatives
2.6 Pharmaceuticals Export Promotion Council (Pharmexcil)
2.7 Vision 2015
3 Leading Players and Comparative Matrix
3.1 Leading Players
3.1.1 Ranbaxy Laboratories Limited (Ranbaxy)
3.1.2 Dr Reddy's Laboratories Limited (Dr Reddy's)
3.1.3 Cipla Limited (Cipla)
3.1.4 Lupin Limited (Lupin)
3.2 Comparative Matrix
3.3 SWOT Analysis



List of Tables

Table 1: World Health Statistics
Table 2: Pharmaceutical Market Share in National Trade (figures in INR cr) (2006-07 - 2010-11)
Table 3: Comparison of International and Indian Prices of Generics Drugs
Table 4: Prices of Bulk Drugs
Table 5: Formulation Packs
Table 6: RandD Expenditures (1995-96 - 2009-10)
Table 7: Dr Reddy's - Total Revenues by Segment (2010-11 - 2011-12)
Table 8: Financial Highlights of the Leading Players



List of Charts

Chart 1: Global Pharmaceutical Market by Region in 2011
Chart 2: Global Pharmaceutical Market by Region in 2008
Chart 3: India's GDP by Sector (2006-2012)
Chart 4: State-wise Distribution of Pharmaceutical Units in India
Chart 5: India Pharmaceutical Sector (2005-06 - 2009-10)
Chart 6: Production and Sales of Pharma CPSUs (2008-09 - 2011-12)
Chart 7: Estimated Size of Medical Equipments Industry (2008-2012)
Chart 8: Indian Pharmaceutical Industry (2002-03 - 2015-16P)
Chart 9: Ranbaxy - Expenditure on RandD Operations (2008 - 2011)
Chart 10: Dr Reddy's - Revenue Distribution by Geographical Mix (FY 2011 and FY 2012)
Chart 11: Cipla - Export Markets in FY 2012
Chart 12: Lupin - Operational Highlights (2008 - 2012)
Chart 13: Lupin - Revenue Breakdown in FY 2012

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation

  • $ 6995
  • Industry report
  • January 2017
  • by GBI Research

Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation Summary Melanoma is a type of cancer that begins in the ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.